Strides receives USFDA approval for Sucralfate Oral Suspension, 1gm/10 mL
May 25, 2024
Source: drugdu
158
Sucralfate is used to treat stomach ulcers,GERD, radiation proctitis, and stomach inflammation and to prevent stress ulcers.
Strides Pharma Science (Strides) recently announced that its stepdown wholly owned subsidiary, Strides Pharma Global, Singapore, has received approval for the generic version of Sucralfate Oral Suspension, 1gm/10 mL, from the United States Food & Drug Administration (USFDA).
The product is bioequivalent and therapeutically equivalent to the Reference Listed Drug (RLD), Carafate 1gm/10mL of AbbVie. Sucralfate is used to treat stomach ulcers, gastroesophageal reflux disease (GERD), radiation proctitis, and stomach inflammation and to prevent stress ulcers.
Sucralfate Oral Suspension, 1gm/10 mL has a market size of ~US$ 124Mn as per IQVIA (March 2024). The Sucralfate Oral Suspension, 1gm/10 mL will be manufactured at the company’s flagship facility in KRS Gardens in Bangalore, India.
https://www.expresspharma.in/strides-receives-usfda-approval-for-sucralfate-oral-suspension-1gm-10-ml
By editor
Copyright©2024 Ddu. All rights reserved.
Read more on
- Taking advantage of the “Eight Measures of Science and Technology”, Haier Health aims to create a flagship of biotechnology December 24, 2024
- Beware of “two sets of prices” providing funding sources for pharmaceutical bribery December 24, 2024
- Is placebo effective? Vertex evaporates $13 billion overnight December 24, 2024
- Aadi Biosciences and WuXi Biologics collaborate to develop 3 new ADC drugs December 24, 2024
- Novo Nordisk’s talent war December 24, 2024
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
